US Stock MarketDetailed Quotes
SONN Sonnet BioTherapeutic
- 4.3300
- +0.0100+0.23%
Close Nov 4 16:00 ET
2.96MMarket Cap-4510P/E (TTM)
4.3300High4.0000Low17.01KVolume4.0200Open4.3200Pre Close71.23KTurnover2.88%Turnover RatioLossP/E (Static)682.66KShares18.719252wk High1.13P/B2.56MFloat Cap4.000052wk Low--Dividend TTM590.57KShs Float329609.2800Historical High--Div YieldTTM7.64%Amplitude4.0000Historical Low4.1880Avg Price1Lot Size
Sonnet BioTherapeutic Key Stats
Quarterly+Annual
YOY
| (Q3)Jun 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 50.27%-3.07M | 115.41%723.79K | 47.73%-3.09M | 23.16%-21.34M | 27.03%-4.56M | 21.12%-6.17M | 16.28%-4.7M | 26.90%-5.92M | -23.15%-27.77M | -5.22%-6.25M |
| Net income from continuing operations | 11.18%-3.51M | 106.45%365.43K | 78.92%-1.17M | 36.64%-18.83M | 50.55%-3.68M | 49.90%-3.95M | 30.96%-5.67M | 10.62%-5.54M | -18.96%-29.72M | -6.95%-7.44M |
| Depreciation and amortization | 10.87%21.04K | 8.60%20.5K | 8.35%19.97K | -18.77%75.75K | 8.58%19.47K | -19.91%18.98K | -27.93%18.87K | -27.56%18.43K | -2.00%93.26K | -27.67%17.93K |
| Other non cash items | --360.16K | --0 | -88.00%12K | -70.97%282K | ---- | ---- | -92.75%12K | -16.67%100K | 155,835.31%971.48K | ---- |
| Change In working capital | 99.28%-17.65K | -68.60%277.48K | -243.90%-2.01M | -43,305.16%-3.12M | -196.70%-951.85K | -270.29%-2.46M | -57.05%883.67K | 75.39%-583.08K | -99.34%7.21K | 46.59%984.37K |
| -Change in receivables | 53.12%-141.65K | -120.67%-183.85K | 195.69%592.46K | 90.34%-69.27K | 94.79%-37.41K | ---302.16K | --889.41K | ---619.12K | ---717.31K | ---717.31K |
| -Change in prepaid assets | 100.77%5.01K | -0.85%349.44K | 225.52%269.12K | 92.59%-33.65K | -38.36%185.29K | 1.53%-654.04K | 432.15%352.43K | 435.20%82.67K | 49.62%-454.27K | 217.76%300.6K |
| -Change in payables and accrued expense | 110.88%141.39K | 138.25%122.61K | -35,299.17%-2.75M | -248.80%-2.4M | -153.15%-786.91K | -1,680.12%-1.3M | -114.05%-320.55K | 100.35%7.82K | -18.17%1.61M | 3.39%1.48M |
| -Change in other current assets | 97.66%-3.64K | --7.02K | ---77.66K | ---414.21K | ---258.84K | ---155.37K | --0 | --0 | --0 | --0 |
| -Change in other current liabilities | -15.56%-18.75K | -1,403.98%-17.75K | -0.14%-17.23K | 38.66%-51.33K | -0.16%-16.72K | 24.39%-16.23K | 94.93%-1.18K | 22.63%-17.2K | -1.98%-83.69K | 22.61%-16.69K |
| -Change in other working capital | --0 | --0 | 50.00%-18.63K | 57.76%-147.81K | 40.63%-37.26K | 40.63%-36.85K | 61.77%-36.45K | 71.30%-37.26K | -2,237.19%-349.94K | 87.02%-62.75K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 50.27%-3.07M | 115.41%723.79K | 47.73%-3.09M | 23.16%-21.34M | 27.03%-4.56M | 21.12%-6.17M | 16.28%-4.7M | 26.90%-5.92M | -23.15%-27.77M | -5.22%-6.25M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0.00%-12K | 45.29%-443.25K | -375.75%-170K | 97.95%-12K | -22,263.43%-810.23K | 1,801.63%61.65K | ||||
| Net intangibles purchase and sale | 0.00%-12K | ---- | ---- | 45.29%-443.25K | -375.75%-170K | 97.95%-12K | ---- | ---- | ---810.23K | --61.65K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 0.00%-12K | ---- | ---- | 45.29%-443.25K | -375.75%-170K | 97.95%-12K | ---- | ---- | -22,263.43%-810.23K | 1,801.63%61.65K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 57.02%2.85M | -99.72%41K | -15.87%3.84M | 423.26%21.01M | -100.44%-17.7K | 1.81M | 14.65M | 4.56M | -90.63%4.01M | -85.42%4.01M |
| Net issuance payments of debt | ---- | ---- | ---- | ---748 | --0 | ---- | ---- | ---- | --0 | --0 |
| Net common stock issuance | -96.68%60.29K | --0 | -15.87%3.84M | 1,040.46%21.01M | -100.96%-17.7K | --1.81M | --14.65M | --4.56M | -95.70%1.84M | -93.31%1.84M |
| Net preferred stock issuance | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --2.17M | ---- |
| Proceeds from stock option exercised by employees | 347,010.48%2.95M | ---- | ---- | --849 | --0 | --849 | ---- | ---- | --0 | --0 |
| Net other financing activities | ---157.5K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 57.02%2.85M | -99.72%41K | -15.87%3.84M | 423.26%21.01M | -100.44%-17.7K | --1.81M | --14.65M | --4.56M | -90.63%4.01M | -85.42%4.01M |
| Net cash flow | ||||||||||
| Beginning cash position | -66.76%3.79M | 77.67%3.02M | -25.50%2.27M | -88.95%3.05M | 34.38%7.02M | -16.47%11.39M | -91.24%1.7M | -88.95%3.05M | 275.82%27.62M | -13.47%5.22M |
| Current changes in cash | 94.69%-231.85K | -92.11%764.79K | 155.25%747.13K | 96.83%-778.62K | -118.57%-4.75M | 48.05%-4.37M | 267.81%9.69M | 83.53%-1.35M | -221.20%-24.57M | -110.06%-2.17M |
| End cash Position | -49.38%3.55M | -66.76%3.79M | 77.67%3.02M | -25.50%2.27M | -25.50%2.27M | 34.38%7.02M | -16.47%11.39M | -91.24%1.7M | -88.95%3.05M | -88.95%3.05M |
| Free cash flow | 50.17%-3.08M | 114.60%723.79K | 47.73%-3.09M | 23.79%-21.79M | 23.55%-4.73M | 26.48%-6.18M | 14.16%-4.96M | 27.97%-5.92M | -26.72%-28.58M | -4.12%-6.19M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data